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Key messages
 ► There is a complex bidirectional interaction 
between commonly used non- antibiotic drugs 
and the gut microbiome.
 ► Commonly used drugs such as proton pump 
inhibitors, metformin, selective serotonin 
reuptake inhibitors and laxatives influence gut 
microbiome composition and function.
 ► Proton pump inhibitor- induced changes in 
the gut microbiome can lead to decreased 
colonisation resistance and the development of 
enteric infections, including Clostridium Difficile 
infections.
 ► Gut microbiome composition is associated with 
antitumour response and the clinical efficacy of 
treatment with immune checkpoint inhibition.
 ► Gut microbes can contribute to drug efficacy 
and safety by enzymatically transforming drug 
structure and altering drug bioavailability, 
bioactivity or toxicity.
 ► Insights into how the gut microbiome interacts 
with commonly used drugs enable interventions 
to modulate the gut microbiome and optimise 
treatment efficacy.
AbsTRACT
The human gut microbiome is a complex ecosystem 
that can mediate the interaction of the human host 
with their environment. The interaction between gut 
microbes and commonly used non- antibiotic drugs is 
complex and bidirectional: gut microbiome composition 
can be influenced by drugs, but, vice versa, the gut 
microbiome can also influence an individual’s response 
to a drug by enzymatically transforming the drug’s 
structure and altering its bioavailability, bioactivity or 
toxicity (pharmacomicrobiomics). The gut microbiome 
can also indirectly impact an individual’s response to 
immunotherapy in cancer treatment. In this review we 
discuss the bidirectional interactions between microbes 
and drugs, describe the changes in gut microbiota 
induced by commonly used non- antibiotic drugs, and 
their potential clinical consequences and summarise how 
the microbiome impacts drug effectiveness and its role 
in immunotherapy. Understanding how the microbiome 
metabolises drugs and reduces treatment efficacy will 
unlock the possibility of modulating the gut microbiome 
to improve treatment.
InTRoduCTIon
In the past decade we have witnessed exciting 
discoveries linking the composition and function of 
the human gut microbiome to numerous common 
diseases and phenotypes. Association studies have 
documented changes in the abundance of various 
gut bacteria in individuals with gastrointestinal 
phenotypes, including inflammatory bowel disease, 
irritable bowel syndrome and colorectal cancer, and 
with diseases of other systems and organs, including 
cardiovascular and metabolic conditions, auto-
immune conditions and psychiatric disorders.1–9 
In addition to association analyses, intervention 
studies and animal studies have proven not only the 
association but also the causality of the gut micro-
biome in relation to several diseases.10 Moreover, 
the influence of intrinsic and extrinsic factors on 
gut microbiome composition is increasingly being 
understood.
One very important recent finding is that many 
commonly used non- antibiotic drugs—such as 
proton pump inhibitors (PPIs) and metformin—
change microbiome composition and function.11 12 
These changes can influence health outcomes (in 
the case of PPIs) or reduce drug efficacy (in the case 
of metformin). At the same time, more data has 
become available showing that the gut microbiome 
can directly influence an individual’s response to 
a specific drug by enzymatically transforming the 
drug’s structure and altering its bioavailability, 
bioactivity or toxicity—a phenomenon now 
referred to as pharmacomicrobiomics (figure 1). 
Finally, the gut microbiome can indirectly impact an 
individual’s response to immunotherapy in cancer 
treatment via its influence on the host’s general 
immune status.13 These exciting new insights into 
the bidirectional interaction between non- antibiotic 
drugs and the gut microbiome are the focus of the 
current review.
bACKgRound
The development of gut microbiome research
Just a few decades ago our ability to analyse the 
role of the gut microbiome in relation to human 
health was mainly defined by large technical chal-
lenges. Historically, microbiome studies were 
performed using culturing methods in which one, 
or a few, bacterial species were isolated and studied 
in relation to a disease. This research produced 
numerous important findings, but our ability to 
analyse other components of the gut ecosystem 
was limited. The development of the technique to 
sequence the bacterial 16S ribosomal RNA gene 
allowed overall taxonomic assessment of the gut 
microbiome, and this has dramatically increased 
our knowledge of the broad variations in micro-
bial composition. More recently, whole genome 
shotgun sequencing, or metagenomic sequencing 
(MGS), has become a powerful methodology for 
studying the microbiome. MGS allows identifica-
tion of not only bacteria, but also viruses, protozoa 
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Figure 1 Schematic overview of different interactions between the gut microbiome and commonly used non- antibiotic drugs. SCFA, short- chain 
fatty acids.
and fungi, and it enables focussed analysis of bacterial genes and 
predicted biological pathways. However, as with all sequencing- 
based methods, MGS results are very dependent on the method 
used to isolate DNA from stool samples, and this is the major 
source of the technical variability in the results of microbiome 
studies.14 Other omics approaches, such as metatranscriptomics, 
metametabolomics and metaproteomics, are also increasingly 
being used to get a comprehensive picture of the gut ecosystem. 
Finally, culturomics analysis, which allows deep characterisation 
of individual associated species and strains, is again becoming 
an important method to understand the role of specific taxa in 
relation to diseases.
Intrinsic and extrinsic factors influencing the gut microbiome
With the aid of next- generating sequencing, gut microbiome 
analysis has been applied to several human cohorts. One 
important finding is the large interindividual variability of the 
gut ecosystem: only a minority of gut microbes are shared across 
the majority of individuals. For example, in a European data 
set of 3000 samples, only 17 bacteria were identified as a core 
microbiome present in >95% of all samples.15 The majority of 
bacteria are rare. Of the 639 species identified in a population 
study of 1135 Dutch individuals, 469 (73%) were present in 
fewer than 10 individuals.16 This high interindividual variability 
potentially leads to variations in the metabolic functions carried 
out by the gut microbiome.
Human cohort- based analysis has further shown that the 
dynamic nature of the gut ecosystem reflects a complex inter-
action of the host with lifestyle, dietary, ecological and other 
factors. Hundreds of intrinsic and environmental factors influ-
ence the gut microbiome in healthy individuals, including diet, 
medication, smoking, lifestyle, host genetics and diseases.15 17 
Among all environmental factors, commonly used drugs play a 
particularly important role in the gut ecosystem.
Association of gut microbiome composition with commonly 
used drugs in human cohorts
Several human cohort studies have reported associations between 
use of specific drugs and altered microbial composition and func-
tional profiles (summarised in table 1). One of the first studies 
to see this was conducted in the Dutch LifeLines- DEEP cohort, 
and this study reported microbial associations to 19 out of 42 
commonly used drugs.17 In addition to antibiotics, many human- 
targeted non- antibiotic drugs were associated with changes in 
microbial composition. The top microbiome- associated drugs 
included PPIs, lipid- lowering statins, laxatives, metformin, beta- 
blockers and ACE inhibitors, and selective serotonin reuptake 
inhibitor antidepressants, and similar associations were also 
observed in a Belgium Flemish cohort15 and in the TwinsUK 
cohort18 (table 1). It is also worth noting that these drug- microbe 
associations were mostly assessed for individual drugs. However, 
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we know that patients often take multiple drugs, and this co- med-
ication may be a source of bias when assessing drug- microbe 
associations. A more recent study further assessed the impact of 
polypharmacy and comorbidities on the gut microbiome.19 This 
study took a more in- depth look by performing a meta- analysis 
of the associations between drug use and the gut microbiome in 
three independent cohorts, including patients with inflammatory 
bowel disease and irritable bowel syndrome, and found 19 of 
the 41 medication categories studied to be associated with the 
gut microbiome. As many of the study participants used multiple 
drugs, a stepwise approach was used to regress out the effect 
of polypharmacy. After statistically correcting for polypharmacy, 
PPIs, metformin, antibiotics and laxatives still showed significant 
associations with microbial features.19
Despite the high consistency of drug- microbe associations 
detected in multiple human cohorts, differences in the esti-
mated effect sizes reflect differences in drug usage in different 
European countries and in different patients. For instance, the 
observed impact of antibiotic use on microbial composition in 
the Belgium Flemish cohort was higher than that in the Dutch 
LifeLines- DEEP cohort, which is line with the fact that the 
prescription rate of antibiotics is higher in Belgium than in the 
Netherlands. Age and gender differences between cohorts also 
have a strong effect on the frequency of drug usage, and there-
fore on the observed results.
CommonLy usEd dRugs InFLuEnCIng ThE guT 
mICRobIomE
Proton pump inhibitors
PPIs are among the most commonly used drugs worldwide and 
are used to treat acid- related disorders such as peptic ulcers, 
gastro- oesophageal reflux and dyspepsia and for prevention of 
non- steroidalanti- inflammatory drug- induced gastroduodenop-
athy and bleeding. Since PPIs are very effective and have a very 
favourable safety profile, their use has increased very rapidly 
over the past few decades. In the Netherlands, two million indi-
viduals (~12% of the population) now use either pantoprazole 
or omeprazole by prescription, and similar usage percentages 
have been reported for other countries such as the UK.20 21 The 
total cost of PPIs in the UK is estimated to be more than £100 
million per year.22 Moreover, as PPIs are available over- the- 
counter in the Netherlands, and in many other countries, the 
total number of PPI users will be much higher than the estimate 
based on prescriptions alone. In recent years, considerable atten-
tion has been paid to the safety profile and potential side effects 
of chronic use of PPIs. Although the relative risk of adverse drug 
response (ADR) is low, the high worldwide number of PPI users 
means that absolute numbers of patients with an ADR can still be 
high. While there are clear evidence- based indications for the use 
of PPIs, it has been suggested that up to 70% of PPI prescriptions 
may be unnecessary,22 with use of PPIs as prophylaxis for stress 
ulcers in patients who do not meet evidence- based prescription 
criteria a major contributor to this. Another important factor 
here is that once PPIs are started there is little re- assessment of 
the original indication for which the PPI was prescribed, and 
subsequent attempts to stop them lead to unnecessary chronic 
use.23 24
The large population- based study from the Netherlands 
showed that PPIs were the drugs most associated to a decreased 
diversity and taxonomical changes in the gut microbiome.17 
Extending this analysis to include 16 s data from a cohort with 
inflammatory bowel disease and a cohort with irritable bowel 
syndrome reproduced these changes across all three cohorts and 
showed that the relative abundance of up to 20% of bacterial 
taxa were altered (either decreased or increased) in PPI users 
compared with non- users.25 Similar results showing a lower 
microbial diversity and lower abundance of gut commensals 
were observed in a study analysing 16 s data from faecal samples 
from 1827 twins.26 In addition, a small cross- over trial in 12 
healthy volunteers showed considerable changes in taxonomy 
after starting PPIs.11
Overall, the taxonomic changes in faecal samples of PPI 
users show a decrease in abundance of commensal bacteria of 
the intestine and an increase of bacteria from the oral cavity. 
These changes include an increase in the families Enterobacte-
riaceae, Enterococcaceae and Lactobacillaceae and a decrease in 
Ruminococcaceae and Bifidobacteriaceae, while the shift toward 
typical oral bacteria is reflected by increases in the species Rothia 
dentocariosa and Rothia mucilaginosa, the genus Actinomyces 
and the family Micrococcaceae.25 Moreover, it appears that the 
observed changes are a class- effect of PPIs, since omeprazole, 
esomeprazole and pantoprazole all showed similar changes. A 
higher dosage also seems to be associated with larger microbial 
changes.19
A recent study that used metagenomic sequence data, allowing 
for both high resolution taxonomy and predicted pathway anal-
ysis, studied the effect of 41 commonly used drugs on the gut 
microbiome and again observed that PPIs accounted for the 
largest number of associations.19 After correcting for the impact 
of concomitant use of other drugs, PPIs were significantly asso-
ciated with 24 taxa and 133 pathways. The predicted functional 
changes included the increase of fatty acid and lipid biosynthesis, 
fermentation nicotinamide adenine dinucleotide (NAD) metab-
olism, biosynthesis of L- arginine and purine deoxyribonucleo-
side degradation. These changes in pathways could be explained 
by the observed changes in the abundance of specific taxa. For 
example, L- arginine biosynthesis was more prevalent in the 
microbiome of PPI users. While several bacterial taxa, including 
Bifidobacterium and Ruminococcus species, are predicted to 
contribute to these pathways, statistical analyses showed that 
only the changes in Streptococcus mutans contributed to the 
predicted pathway changes due to PPI use.19 The reduction of 
gastric acidity induced by PPIs is thought to be responsible for 
the observed microbial changes since it enables oral bacteria to 
colonise the gut microbiome, leading to changes in taxonomic 
homoeostasis (figure 1). This is supported by the observation of 
an ‘oralisation’ of the gut microbiome in PPI users.25 However, 
an in vitro study assessing the direct effects of commonly used 
drugs, including PPIs, on gut commensals showed marked 
changes in bacterial growth rates, implying there is also a direct 
effect that is potentially mediated through binding of PPIs to 
bacterial H+/K+ATP ases.27
It is important to recognise that PPI- induced changes in the 
microbiome might actually be contributing to clinically important 
diseases. For example, previous studies defined changes in the 
gut microbiome that lead to a decreased colonisation- resistance 
to enteric infections, including Clostridium difficile, Campy-
lobacter and Salmonella, which are similar to the ones now 
observed in PPI users.28 29 In PPI users, the ORs are estimated to 
be 1.5 to 1.8 for C. difficile and 2.0 to 4.0 for the other patho-
genic bacteria.30 As it is known that C. difficile infections develop 
in the altered gut microbial environment following the admin-
istration of antibiotics,31 this could potentially also be true in 
the setting of PPI use. In addition, PPI initiation and withdrawal 
influences the clinical course in decompensated liver cirrhosis, 
potentially through changes in the gut microbiota.32 Finally, 
increased use of PPIs in early childhood may induce long- term 
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changes in the developing gut microbiome, which can lead to 
obesity in later life.33
While the efficacy and safety profiles of PPIs are still very 
favourable when they are prescribed for evidence- based indi-
cations, the medical community should start to rethink their 
widespread and chronic use and their over- the- counter avail-
ability. We have come to the point where we need to carefully 
assess the long- term effects of PPI- induced changes in the micro-
biome in up to one- fifth of the population in western society, 
a shift that has taken place in a relative short period of time in 
human history, and specifically examine the effects of changing 
the developing gut microbiome in early life and its influence on 
health and disease in later life.
metformin
Metformin is an oral blood glucose- lowering compound used in 
the treatment of type 2 diabetes (T2D). While its exact working 
mechanism is complex, and not fully understood, metformin 
does inhibit liver gluconeogenesis, and studies increasingly 
suggest that some of its beneficial effects are mediated by the 
gut microbiota.34 35 Compared with PPIs, which are used for a 
wide number of indications or symptoms, metformin is (almost) 
exclusively used in the setting of diabetes, making it harder 
to disentangle the effect of the drug on the microbiome from 
changes in the gut microbiome that are related to the underlying 
disease. However, this has been done by a landmark study, which 
showed that previously observed changes in the gut microbiome 
thought to be driven by the underlying T2D were actually caused 
by the use of metformin.12
In an additional intervention study in healthy volunteers, use 
of metformin resulted in a change in >80 species compared with 
a control group receiving placebo. Notably, metformin treatment 
significantly increase Escherichia coli and lowers Intestinibacter 
abundance, which is in line with findings from cross- sectional 
cohorts that compared untreated patients to metformin- treated 
patients with T2D.12 36 Subsequently, the authors transplanted 
faecal samples from metformin- treated or placebo- treated 
donors into germ- free mice and observed lower blood glucose 
levels in the mice that received faecal samples from metformin- 
treated volunteers, implying a direct effect of the gut microbiome 
on blood glucose levels. This effect is thought to be mediated by 
metformin’s effect on short- chain fatty acid (butyrate)- producing 
bacteria and the abundance of Akkermansia muciniphila, as well 
as through common biological pathways and genes encoded in 
different metformin- affected bacteria, for example, metallopro-
teins or metal transporters. Moreover, it is clinically well known 
that up to one- third of patients taking metformin report gastro-
intestinal side effects like diarrhoea, bloating and nausea, and the 
identified metformin- induced changes, including the increase 
of virulence factors and gas metabolism genes (mainly derived 
from an increase of E. coli species), can contribute to these side 
effects.12 36
The intertwined relationship between metformin and the gut 
microbiome shows how a commonly used drug can change the 
gut microbiome and explain part of the drug’s therapeutic func-
tion, as well as some of its side effects. It also emphasises the need 
to rigorously control for confounders like drug use (including of 
metformin, antibiotics, PPIs and other drugs) when performing 
microbiome studies looking at specific diseases or conditions.
other commonly used non-antibiotic drugs
Large population- based microbiome studies using cross- sectional 
data from cohorts from the UK, the Netherlands and Belgium 
have assessed hundreds of factors, including drug use. In addi-
tion to PPIs and metformin, these studies have shown that other 
commonly used drugs, including laxatives, statins, antidepres-
sants and opioids, can explain some of the variability in gut 
microbiome composition.15 18 37
When considering microbial changes induced by the use 
of laxatives, one should take into account the fact that intes-
tinal transit time, stool consistency and bacterial quantities 
(eg, microbial load per sample) all influence microbiome 
features.38 39 For example, increased abundances of Bacteroides 
species are observed in individuals taking laxatives, but also 
in low consistency stool samples. However, in an independent 
study of mice exposed to polyethylene glycol (PEG) showed a 
similar increase in Bacteroides. In this study, the induction of 
mild osmotic diarrhoea by administration of PEG induced long- 
term changes in the gut microbiome, transient disruption of 
the mucus barrier and subsequent innate and adaptive immune 
responses.40 After PEG administration, the S24-7 Family 
(within the order Bacteroidales) disappeared and was replaced 
entirely by outgrowth of the family Bacteroidaceae. This effect 
was permanent unless the S24-7 Family was replaced. Other 
taxa, like Verrucomicrobia and Gammaproteobacteria, showed 
transient changes, but eventually returned to their initial levels. 
Scarce human data in patients taking bowel preparations have 
also shown short- term transient changes in microbiome diver-
sity metrics, but detailed studies are lacking.41 However, given 
the findings in mice, it is likely that the use of laxatives has both 
short- term and long- term effects on gut microbiome compo-
sition that are independent of stool consistency and bacterial 
quantities per sample.
ThE guT mICRobIomE InFLuEnCEs CommonLy usEd 
dRugs
Emergence of pharmacomicrobiomics
Over the past few decades, pharmacogenomics has become a 
well- established field that studies how human genome variations 
affect drug disposition and action. With the increasing recog-
nition of the gut microbiome as the second human genome, 
the concept of pharmacomicrobiomics has been introduced as 
a natural expansion of pharmacogenomics. While this field is 
attracting new attention, the idea that the gut microbiome can 
impact drug efficacy can be dated back to 1937 and the discovery 
of the impact of gut microbes on the activation of the antibacte-
rial drug prontosil.42 43 Orally administered drugs pass through 
the upper gastrointestinal track and continue into the intestinal 
tract, where they encounter the thousands of different species 
residing in our gut (figure 1). The consequent interactions are 
bidirectional. On the one hand, drugs can change intestinal 
microenvironments and affect bacterial growth, composition 
and function, as described above. On the other, the gut micro-
biome can directly influence an individual’s response to a specific 
drug by enzymatically transforming drug structure and thereby 
altering its bioavailability, bioactivity or toxicity.44 Unlike human 
genetics, the gut microbiome is modifiable, making it an attrac-
tive therapeutic target to optimise therapy.
The bidirectional interaction between drugs and microbes in 
in vitro and animal studies
In parallel with the gut- microbe associations observed in 
humans, several in vitro and animal studies have revealed the 
action modes of drug- microbe interactions and the potential 
consequences for drug efficacy and safety.
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Figure 2 Bidirectional effects of commonly used drugs. X- axis shows the number of bacterial strains (out of 40 strains) whose growth rate has 
been shown to be affected by a specific drug in vitro. Information extracted from Maier L, et al Nature 2018;555:623–827. Y- axis shows the number 
of bacterial strains (out of 76 strains) that can metabolise a specific drug compound in vitro. Information extracted from Zimmermann et al Nature 
2019;570:462–746.
Suggested mechanisms for drug impact on the gut microbiome
Drug usage may influence gut microbial compositions in different 
ways, and at least two action modes have been proposed. The first 
mode is that drugs can result in the translocation of the micro-
biome from other body sites to the gut. As described above, PPIs 
can reduce the acidity barrier of the stomach, which allows oral 
microbes pass through the stomach to the gut, thereby inducing 
microbial dysbiosis. The second action mode, which might be 
the dominant one, is that drugs can change intestinal microen-
vironments and directly affect bacterial growth. For instance, 
metformin has been found to promote the growth of short- chain 
fatty acid producers in the gut, with these bacteria ultimately 
contributing to the therapeutic effect of metformin in improving 
insulin resistance and glucose homoeostasis. This second action 
mode can be bidirectional. Instead of promoting growth of 
certain bacteria, drugs can also inhibit the growth of specific 
bacteria, for example, showing antimicrobial activities as anti-
biotics. This was demonstrated by a landmark high- throughput 
study27 in which the authors systematically assessed the antimi-
crobial effects of over 1000 drugs, including 835 human- targeted 
drugs that act by targeting human cells. Notably, 24% of these 
drugs showed antibacterial activity, affecting the growth rate of 
at least one of the 40 bacterial strains under study. Among them, 
eight drugs seemed to be toxic to bacteria, affecting the growth 
rate of at least 50% of the strains. These drugs included four 
antineoplastic agents (daunorubicin, 5- fluorouracil, streptozo-
tocin and floxuridine), two anti- inflammatory and antirheumatic 
drugs (auranofin and diacerein), one antigout drug (benzbroma-
rone) and one drug for peptic ulcer disease (oxethazaine). This 
result strongly highlights the side effects of cancer therapy on the 
gut microbiome, as these drugs are often cytotoxic.
Suggested mechanism of microbial impact on drug efficacy and 
safety
It has been shown that gut microbes can contribute to drug 
efficacy and safety by enzymatically transforming drug struc-
ture and altering drug bioavailability, bioactivity or toxicity. For 
instance, the oral antiviral drug brivudine can be metabolised to 
bromovinyluracil by both the host and the gut microbiota, with 
the latter exerting hepatic toxicity. By comparing the plasma and 
liver concentrations of brivudine and bromovinyluracil between 
conventional and germ- free mice, Zimmermann et al determined 
that 70% of brivudine toxicity is attributable to gut microbes, 
particularly to Bacteroides thetaiotaomicron and Bacteroides 
ovatus.45 The same research group further conducted a system-
atic analysis to test the metabolic capacity of 76 gut microbial 
strains on 271 orally administered drugs46 and found that 176 
drugs (66%) were metabolised by a least one kind of bacterial 
stain. The drugs that were metabolised by most microbes in vitro 
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Figure 3 The gut microbiome is involved in modulating the clinical 
response to cancer immunotherapy. CTLA-4,cytotoxic T lymphocyte 
antigen 4; FMT,faecal microbiome transplantation; PD-1, programmed 
cell death protein 1; PD- L1, programmedcell death protein 1 ligand.
included PPIs (pantoprazole, omeprazole and tenatoprazole), the 
chemotherapeutic drug melphalan, the antimalarial artemisinin 
and the Parkinson’s drug mesylate. These could be metabolised 
by almost all the bacterial strains under study. The super drug- 
metabolising strains were Bacteroides dorei (strain DSM17855) 
and Clostridium sp, which could metabolise 164 and 154 drugs, 
respectively.
All in all, the results of these two independent studies, one 
assessing the antimicrobial effect of drugs27 and one assessing 
bacterial ability to metabolising the drugs,46 show that sustain-
able drugs that can function under bacterial metabolism but do 
not show strong antimicrobial effect (figure 2). However, bidi-
rectional effects are pronounced for several drugs, for example, 
levodopa.
The bidirectional effect of the gut microbiome: the example 
of levodopa
Levodopa, used for the treatment of Parkinson disease, is an 
intriguing example of microbial impact on drug efficacy. After 
oral administration, levodopa needs to be absorbed via the small 
intestine so it can cross the blood- brain barrier and enter the 
brain, where the human enzyme aromatic amino acid decar-
boxylase converts levodopa to the therapeutically active dopa-
mine. The bioavailability of levodopa to the brain is a key factor 
for drug efficacy, and levodopa is often co- administered with 
catechol metabolism inhibitors, for example, carbidopa and 
entacapone, to inhibit its off- site metabolism. In recent years, 
research has shown that the microbial decarboxylases that are 
part of gut microbial organisms appear to be able to metabo-
lise levodopa. Novel bacterial L- dopa metabolism by tyrosine 
decarboxylases (tyrDCs) has been identified, dominantly driven 
by Enterococcus faecalis.47 Conversely, mutating these tyrDCs 
in E. faecalis can block this bacterial L- dopa- to- dopamine 
metabolism, thereby improving drug efficacy. In addition to 
Enterococcus species, tyrDCs are also present in Lactobacillus 
species, although Enterococcus and Lactobacillus species show 
considerable differences in the efficiency of their L- dopa metab-
olism.48 Moreover, gut bacterial metabolism of L- dopa not only 
decreases drug availability, it also induces ADRs. Eggerthella 
lenta and 10 other bacterial species were found to contain the 
dopamine- dehydroxylating enzyme, which can further convert 
bacterial- derived dopamine to m- tyramine and thereby induce 
hypertensive crisis.47
Interestingly, in vitro, there is also a direct metabolising effect 
of bacteria on the catechol metabolism inhibitors carbidopa 
and entacapone that are often co- administered with levodopa. 
Numerous microbes can metabolise entacapone. E. faecalis, for 
instance, metabolises both levodopa and entacapone at an effi-
ciency of 98.9%.46 Conversely, entacapone can also inhibit the 
growth rate of 10 different species,27 including Ruminococcus 
torques, which in turn metabolises entacapone at 84% effi-
ciency.46 These results show the complicated bidirectional inter-
action between drugs and gut microbes.
ThE guT mICRobIomE And AnTITumouR REsPonsE In 
CAnCER ImmunoThERAPy
We have described how commonly used non- antibiotic drugs 
can influence the gut microbiome composition and how the gut 
microbiome composition can influence drug availability and effi-
cacy. In addition, there is also increasing evidence that the gut 
microbiome is involved in modulating the clinical response to 
cancer therapy. This occurs specifically in the setting of treat-
ment with immunotherapy using monoclonal antibodies that 
target programmed cell death protein 1 (PD-1) and its ligand 
(PD- L1) or the cytotoxic T lymphocyte antigen 4 (CTLA-4).49 50 
Here the postulated mechanism of action lies in the role of the 
gut microbiome in fine- tuning the general host immune status 
and subsequently in antitumour activation of the immune system 
on checkpoint inhibition (figure 3).
The first breakthrough studies that provided compelling 
evidence that the gut microbiome influences tumour response 
were conducted in mice, and these findings were later substan-
tiated in human clinical and microbiome data. It was observed 
that the efficacy of anti- CTLA-4 therapy was reduced in germ- 
free mice and in specific pathogen- free mice that were treated 
upfront with antibiotics.51 The mice were then orally fed the 
species B. fragilis, combined with Burkholderia cepacia or B. 
thetaiotaomicron, which induced a Th1- mediated immune 
response and maturation of intratumorous dendritic cells. This, 
in turn, yielded improved antitumour reactivity to anti- CTLA-4 
therapy. In the following phase, the authors transferred faecal 
material of patients with high levels of B. fragilis into mice, and 
this indeed resulted in improved antitumour response to anti- 
CTLA-4 therapy.51
At the same time, similar results were published in the setting 
of another anticancer drug that induces PD- L1 blockade. In this 
case a higher relative abundance of Bifidobacterium species in 
mice resulted in better efficacy of PD- L1 blockade.52 This effect 
could also be induced by faecal microbiome transplantation or 
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cohousing of mice with beneficial species or administration of 
Bifidobacterium- containing probiotics, again through matura-
tion of dendritic cells and increased T- cell reactivity. A more 
recent study showed similar beneficial results after supplementa-
tion with A. muciniphila.53 In the human setting, the role of the 
gut microbiome is further substantiated by the observation that 
patients treated with checkpoint inhibitors who had received 
treatment with antibiotics prior, during, or after PD- L1 or PD-1 
inhibition had lower progression- free survival compared with 
patients who had not been treated with antibiotics.53
A series of subsequent papers have reported the baseline gut 
microbial composition and specific taxa associated to response or 
non- response to checkpoint inhibitors. These included, among 
many others, Bifidobacterium longum, Enterococcus faecium 
and B. thetaiotaomicron, which were positively correlated with 
response to checkpoint inhibitors, and E. coli, which was nega-
tively correlated.54–57 It has to be noted that at present there is 
very little overlap in the associated species reported by different 
studies, and there are several explanations for this. It could be due 
to the lack of standardised sampling protocols between studies, 
the lack of standardised statistical correction for confounding 
factors and/or low statistical power due to relatively small 
sample sizes. Larger studies aimed at overcoming these issues 
are currently underway (eg,  ClinicalTrials. gov: NCT03643289).
The precise mechanisms by which the gut microbiome influ-
ences immunotherapy response still have to be elucidated. 
It is thought that the microbiome is partially responsible for 
general peripheral immune homoeostasis and that microbial 
antigens induce exaggerated T- cell reactivity, which can support 
tumour- specific responses. In mouse models it has been shown 
that both innate and adaptive immune cells exposed to specific 
gut microbes can infiltrate the tumour microenvironment and 
produce chemotactic factors like CXCL9, CXCR3, CCR9 
and CXCL10, which induce trafficking of immune cells to 
the tumour site.53 58 Another hypothetical mechanism is cross- 
reactivity between microbial and tumour- associated antigens.59 
Finally, the gut microbiome can produce metabolites, such as 
short- chain fatty acids, that can have systemic effects on host 
immunity.13
The finding that the gut microbiome influences clinical 
responses implies that modulating the gut microbiome could 
potentially improve, or worsen, survival after treatment with 
checkpoint inhibitors. Intriguingly, both the use of antibiotics 
and of PPIs has been associated with shorter survival and disease- 
free survival after treatment with immune checkpoint inhibi-
tors.60 On the other hand, the potential to improve survival has 
resulted in the initiation of multiple ongoing intervention trials. 
These include studies analysing the efficacy of dietary inter-
ventions, the use of specific probiotics and even faecal micro-
biome transplantation before initiation of checkpoint inhibition 
for metastatic cancer. A phase 1/2 trial is ongoing with an oral 
microbial product (VE800) that contains 11 clonal commensal 
bacterial strains shown to induce CD8 + T cell responses and 
invigorate the efficacy of checkpoint inhibition. It is worth 
noting the exceptional speed at which the identification of these 
11 strains—published only in 2018—has led to a phase 1/2 inter-
vention trial in the human setting58 ( ClinicalTrials. gov Identifier: 
NCT04208958).
Recognition that the microbiome plays a role in antitumour 
efficacy is a major scientific breakthrough that has changed our 
thinking on how to predict and improve cancer immunotherapy. 
Understanding the underlying mechanisms will be crucial, and 
results of interventional trials will aid in optimising immuno-
therapy treatment.
ConCLusIons
We have described the complex bidirectional interaction between 
commonly used non- antibiotic drugs and the gut microbiome 
and described different examples to highlight specific mecha-
nisms. Clinicians need to be aware that it is not only antibiotics 
that influence the gut microbiome, non- antibiotic drugs can 
also change the gut microbiome and ultimately lead to impaired 
health outcomes. At the same time, the pharmacomicrobio-
mics field is emerging, and a deeper understanding of how the 
microbiome metabolises drugs or ameliorates the efficacy of, for 
example, anticancer treatment, will open up the possibility of 
modulating the gut microbiome to improve treatment efficacy. 
Clinical trials are already underway, and their results will influ-
ence clinical practice in the foreseeable future.
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